Fintel reports that on October 18, 2024, Jones Trading initiated coverage of Rapport Therapeutics (NasdaqGM:RAPP) with a Buy recommendation.
Analyst Price Forecast Suggests 37.84% Upside
As of September 25, 2024, the average one-year price target for Rapport Therapeutics is $35.70/share. The forecasts range from a low of $35.35 to a high of $36.75. The average price target represents an increase of 37.84% from its latest reported closing price of $25.90 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.61.
What are Other Shareholders Doing?
Arch Venture holds 3,729K shares representing 10.19% ownership of the company.
Cormorant Asset Management holds 2,940K shares representing 8.04% ownership of the company.
Capital International Investors holds 2,603K shares representing 7.12% ownership of the company.
Johnson & Johnson holds 2,498K shares representing 6.83% ownership of the company.
Sofinnova Investments holds 1,952K shares representing 5.34% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
